摘要
目的研究头孢曲松(第3代头孢类抗生素)/舒巴坦(β内酰胺酶抑制剂)复方制剂对产超广谱β内酰胺酶(ESBL)体外抗菌活性。方法以肉汤试管稀释法测定MIC;将指定浓度药物与菌液混合培养,绘制时间杀菌曲线和药代动力学杀菌曲线。结果头孢曲松单体和头孢曲松/舒巴坦复方制剂对产ESBL菌株的MIC50与MIC90分别为>128、32mg·L-1与>128、64mg·L-1;头孢曲松/舒巴坦较头孢曲松单体对细菌生长有明显抑制作用;头孢曲松/舒巴坦药代动力学模拟组和头孢曲松/舒巴坦以2∶1恒定变化组的杀菌效果相似,且均很好。结论头孢曲松/舒巴坦体内药代动力学模拟组中,舒巴坦浓度随时间延长很快降低,并未对产ESBL大肠埃希菌的杀菌效果产生明显影响。
Objective To study of antimicrobial activity of ceftriaxone plus sulbactam（CRO/SCB ,2∶1） on extended-spectrum β-lactamase （ESBL）-producing E.coli in vitro. Methods The MICs were determined by broth macrodilution method. The bacteria were resuspended in MH broth with drugs for drawing the time-kill curve and pharmacokinetic time-kill curve. Results The MIC50 and MIC90 of ceftriaxone and ceftriaxone/sulbactam against ESBL-producing Escherichia coli and Klebsiella pneumonia were 〉128 and 32 mg·L^-1 ,〉128 and 64 mg·L^-1 According to the time-kill studies, ceftriaxone/sulbactam groups displayed obvious antibacterial activities. For the pharmacokinetic time-kill curve, the group of ceftriaxone/pharmacokinetic procedure and the group in which ceftriaxone/sulbactam is keeping in the proportion 2：1 displayed similar and excellent antibacterial activity on ESBL-producing E. coli. Conclusion The fast decline of sulbactam concentration in ceftriaxone/sulbactam whose concentration is pharmacokinetic procedure does not obviously decrease antibacterial activity to ESBL-producing E. coli.
出处
《中国临床药理学杂志》
CAS
CSCD
北大核心
2009年第5期426-429,共4页
The Chinese Journal of Clinical Pharmacology
关键词
头孢曲松
舒巴坦
产超广谱Β内酰胺酶
大肠埃希菌
杀菌活性
ceftriaxone
sulbactam
extended-spectrum β-lactamase
Escherichia coli
antimicrobial activity
